While neoadjuvant immunotherapy shows astounding success in MSI-high rectal cancer, the primary difficulty for clinicians lies in accurately assessing complete response via endoscopy and MRI, and managing unique complications like mucin pools or stenosis, rather than simply administering the treatment.
A meta-analysis of over 3,000 patients shows that neoadjuvant chemotherapy for MSS colon cancer provides a 5% improvement in survival. This benefit is clinically meaningful and equivalent in magnitude to the landmark addition of oxaliplatin to 5-FU in the original MOSAIC trial.
Unlike rectal cancer where MRI aids response assessment, MSI-high colon cancer lacks a reliable imaging modality to confirm a pathologic complete response after neoadjuvant immunotherapy. This makes a "watch and wait" approach far more challenging and not currently recommended outside of a clinical trial.
Data from the CO21 trial shows a structured exercise program provides a 7% improvement in overall survival for high-risk colon cancer patients. This non-pharmacological intervention demonstrates a greater survival benefit than the established 5% gain from adding oxaliplatin to chemotherapy.
While the ATOMIC trial established FOLFOX plus atezolizumab as a new standard for adjuvant therapy in MSI-high colon cancer, its design lacked an immunotherapy-only arm. This leaves a critical, unanswered question about the actual contribution and necessity of the chemotherapy component.
While the ATOMIC trial combined FOLFOX with atezolizumab, clinicians should not de-escalate by simply dropping oxaliplatin. Historical data suggests single-agent 5-FU is ineffective and potentially harmful in MSI-high patients, a risk that is not presumed to be overcome by adding immunotherapy.
Despite the success of ctDNA-guided de-escalation in Stage II disease, the DYNAMIC-3 trial in Stage III patients showed that ctDNA-negative patients had worse outcomes with de-escalated therapy. This serves as a critical warning against this de-escalation strategy in higher-risk patients for now.
When a patient becomes ctDNA positive during surveillance after completing adjuvant therapy, the optimal next step is not immediate systemic chemotherapy. Clinicians should instead initiate intensive imaging (e.g., CT, PET) to identify a potential radiographic recurrence, which may be isolated and resectable.
A significant challenge in assessing complete response after neoadjuvant immunotherapy for rectal cancer is the presence of mucin pools. These imaging abnormalities can persist for up to two years, mimicking residual tumor and complicating decisions about non-operative management.
A potential complication of successful neoadjuvant immunotherapy in rectal cancer is the development of stenosing scar tissue. This can block the lumen, making endoscopic surveillance impossible and necessitating surgery for a patient who may have otherwise achieved a complete clinical response.
Following the ALASKA trial, which demonstrated a disease-free survival benefit, NCCN guidelines now recommend considering aspirin for early-stage colon cancer patients with a PIK3CA mutation. This is a significant shift toward molecularly guided, non-chemotherapeutic adjuvant therapy that is not yet widely adopted.